Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Large Drop in Short Interest

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 255,600 shares, a decline of 14.2% from the September 30th total of 297,800 shares. Approximately 1.3% of the company’s stock are sold short. Based on an average daily trading volume, of 65,700 shares, the days-to-cover ratio is currently 3.9 days.

Institutional Trading of Aileron Therapeutics

Several institutional investors have recently modified their holdings of ALRN. KG&L Capital Management LLC acquired a new stake in Aileron Therapeutics during the 3rd quarter worth $46,000. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Aileron Therapeutics during the second quarter worth about $4,925,000. Nantahala Capital Management LLC increased its position in shares of Aileron Therapeutics by 82.1% during the second quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock worth $1,286,000 after purchasing an additional 209,367 shares in the last quarter. Warberg Asset Management LLC purchased a new stake in shares of Aileron Therapeutics in the 2nd quarter valued at about $86,000. Finally, Texas Capital Bank Wealth Management Services Inc boosted its position in shares of Aileron Therapeutics by 65.9% in the 1st quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company’s stock valued at $174,000 after purchasing an additional 10,398 shares during the period. Hedge funds and other institutional investors own 90.89% of the company’s stock.

Aileron Therapeutics Stock Down 5.6 %

Shares of NASDAQ:ALRN opened at $3.85 on Thursday. The stock has a market cap of $83.22 million, a price-to-earnings ratio of -1.21 and a beta of 2.35. The firm’s 50 day moving average price is $3.18 and its 200 day moving average price is $3.23. Aileron Therapeutics has a fifty-two week low of $1.01 and a fifty-two week high of $7.42.

Aileron Therapeutics (NASDAQ:ALRN) last issued its earnings results on Wednesday, August 14th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.20). On average, equities analysts anticipate that Aileron Therapeutics will post -1.41 EPS for the current year.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).